Calan (Verapamil Injection) and Emend Intravenous
Determining the interaction of Calan (Verapamil Injection) and Emend Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Verapamil may increase the blood levels and effects of fosaprepitant. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects such as nausea, constipation, diarrhea, or loss of appetite. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme. According to the manufacturer, administration of a single 125 mg dose of aprepitant on day 5 of treatment with the potent CYP450 3A4 inhibitor ketoconazole (400 mg/day for 10 days) resulted in a 5-fold increase in mean aprepitant systemic exposure (AUC) and a 3-fold increase in mean terminal half-life. In patients with mild to moderate hypertension, coadministration of aprepitant (approximately 230 mg once a day) and the moderate inhibitor diltiazem (120 mg three times a day for 5 days) resulted in a 2-fold increase in the AUC of aprepitant and a 1.7-fold increase in that of diltiazem. No clinically significant changes in ECG, heart rate, or blood pressure were observed beyond those induced by diltiazem alone.
MANAGEMENT: Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.
- "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.
- "Product Information. Emend for Injection (fosaprepitant)." Merck & Company Inc, West Point, PA.
Generic Name: verapamil
Brand name: Calan, Calan SR, Isoptin SR, Verelan, Isoptin, Isoptin IV, Covera-HS, Verelan PM
Synonyms: Calan Immediate-Release Tablets, Calan
Generic Name: fosaprepitant
Brand name: Emend for Injection
Synonyms: Fosaprepitant
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Calan (Verapamil Injection)-Emflaza
- Calan (Verapamil Injection)-Emflaza (Deflazacort Oral Suspension)
- Calan (Verapamil Injection)-Emflaza (Deflazacort Tablets)
- Calan (Verapamil Injection)-Emicizumab
- Calan (Verapamil Injection)-Emicizumab-kxwh
- Calan (Verapamil Injection)-Emicizumab-kxwh Subcutaneous
- Emend Intravenous-Calan SR
- Emend Intravenous-Calaspargase Pegol
- Emend Intravenous-Calaspargase Pegol-mknl
- Emend Intravenous-Calci-Chew
- Emend Intravenous-Calcibind
- Emend Intravenous-Calcidol